scholarly journals Comparison of the CMV Brite Turbo Assay and the Digene Hybrid Capture CMV DNA (Version 2.0) Assay for Quantitation of Cytomegalovirus in Renal Transplant Recipients

2000 ◽  
Vol 38 (10) ◽  
pp. 3743-3745 ◽  
Author(s):  
Stephen K. N. Ho ◽  
Fu-Keung Li ◽  
Kar-Neng Lai ◽  
Tak-Mao Chan
Keyword(s):  
Renal Transplant ◽  
Turnaround Time ◽  
Small Sample ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Hybrid Capture ◽  
Pp65 Antigenemia ◽  
Version 2.0 ◽  
Blood Specimens ◽  
Cmv Disease

We compared the CMV Brite Turbo Kit (BT) and the Digene Hybrid Capture CMV DNA (version 2.0) assay (HC2) in the quantitation of pp65 antigenemia and cytomegalovirus (CMV) DNA levels in immunosuppressed renal transplant recipients. Of 123 blood specimens collected from 24 renal transplant recipients, BT and HC2 assays detected 35 and 39 positive samples, respectively. The overall concordance rate between the two assays was 90%. Discordant results were observed at low levels of viremia, so that 8 samples were HC2 positive but BT negative and another 4 were BT positive but HC2 negative. There was good correlation (R 2 = 0.766; P < 0.01) between the levels of CMV DNA and pp65 antigenemia in the 31 concordant positive samples. Correlation between results obtained with the two assays was confirmed by longitudinal studies for a patient who developed clinical CMV disease. HC2 may be more sensitive at low viremia levels and allow earlier detection of impending CMV disease. The BT assay offered the advantage of a rapid (2-h) turnaround time. We conclude that BT and HC2 assays have similar sensitivity and efficacy in the diagnosis and monitoring of CMV infection and disease in renal transplant recipients. While the HC2 assay would be appropriate for centers that handle a large number of samples, the BT test may be more suitable for small sample numbers or when results are needed urgently.

Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease

2018 ◽  
Vol 20 (5) ◽  
pp. e12929 ◽  
Author(s):  
Jose O. Reusing ◽  
Emanoela B. Feitosa ◽  
Fabiana Agena ◽  
Lígia C. Pierrotti ◽  
Luiz S. F. Azevedo ◽  
...  
Keyword(s):  
Risk Factors ◽  
Renal Transplant ◽  
Induction Therapy ◽  
Therapy Outcome ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Cmv Disease

scholarly journals Prophylaxis of Cytomegalovirus in Renal Transplant Recipients

1993 ◽  
Vol 4 (suppl c) ◽  
pp. 51-57
Author(s):  
Allan S MacDonald ◽  
David L Nicol ◽  
Philip Belitsky ◽  
Spencer Lee
Keyword(s):  
Renal Transplant ◽  
Low Dose ◽  
Risk Groups ◽  
High Titre ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Cmv Infection ◽  
Hyperimmune Globulin ◽  
Low Incidence ◽  
Cmv Disease

The incidence and outcome of cytomegalovirus (CMV) infection and disease is compared in renal transplant recipients in relation lo the use of prophylaxis wiU1 high titre anti-CMV immunoglobulin. Seventy-three CMV-negative recipients (R-) who received kidneys from CMV-posilive donors (D+) were given prophylactic CMV hyperimmune globulin inlravenously al three-week intervals lo six monilis. They also received Lhree months of oral low dose acyclovir as did the remaining 288 patients who did nol receive hyperimmune globulin. There was a low incidence of CMV disease which did not differ between groups (D+R-, 10%: D+R+, 5 .5%, D- R+, 7%: D- R-, 0.8%). The major risk factor was the use of OKT3 to treat rejection. CMV disease was seen in 22% of this group (11 of 50) . compared with only 2% (seven of 311) of those not requiring OKT3. There was only one CMV-related death. but palients with CMV disease had a reduced graft survival rate (62% versus 90%). CMV hyperimmune globulin added lo acyclovir appears to reduce the incidence of CMV disease in high risk renal recipients (D+R-) in the lower risk groups.

scholarly journals Cytomegalovirus Disease Amongst Renal Transplant Recipients in Australia and New Zealand

2008 ◽  
Vol 1 ◽  
pp. VRT.S920 ◽  
Author(s):  
H. Seale ◽  
D.E. Dwyer ◽  
J.R. Chapman ◽  
C.R. MacIntyre
Keyword(s):  
New Zealand ◽  
Renal Transplant ◽  
Hospital Admissions ◽  
Univariate Analysis ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Transplant Patients ◽  
Suitable Target ◽  
Hospital Morbidity ◽  
Cmv Disease

Cytomegalovirus (CMV) is a significant pathogen causing disease in renal transplant patients. The highest incidence of CMV disease occurs during the first 3 months post-transplant and is most problematic in CMV-naïve transplant recipients. In this study, we conducted a retrospective review of two databases, the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) and the National Hospital Morbidity Database, from the Australian Institute of Health and Welfare (AIHW), to examine CMV in renal transplant recipients. The first source looked at CMV serostatus at the time of transplantation and the second recorded hospital admissions for recipients with invasive CMV disease. From the ANZDATA registry, we obtained information from 13,530 renal transplants recipients from 1980 to 2004. Of these recipients, 7808 had a known CMV serostatus, of which 65.7% (5134/7808) had a positive sero antibody status and 34.2% (2674/7808) had a negative sero antibody status. In univariate analysis, factors significantly associated with renal rejection were being male, recipient age <50 years, being diabetic, being diagnosed with cancer at some point and having a positive EBV status. Positive CMV serostatus was not a contributing factor. Between 1993 and 2001 there were 1445 renal transplant recipients hospitalized in Australia with a diagnosis of CMV disease, of which 38% (554/1445) had CMV disease as a principal diagnoses. The average annual rate of admissions with any diagnosis was 3871 episodes per 100,000 people living with a functioning graft. Preventative strategies for CMV in renal transplant recipients should be a priority. New vaccines for CMV may soon be available and renal transplant recipients would be a suitable target group for vaccination.

A longitudinal prospective study of cytomegalovirus pp65 antigenemia in renal transplant recipients

1993 ◽  
Vol 6 (4) ◽  
pp. 185-190 ◽  
Author(s):  
GREGOR Bein ◽  
ANDREAS Bitsch ◽  
JOCHEM Hoyer ◽  
JIIRGEN Steinhoff ◽  
LUTZ Fricke ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Prospective Study ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Pp65 Antigenemia
Sign in / Sign up

Export Citation Format

Share Document